Genprex (GNPX) Cash from Financing Activities (2016 - 2026)
Genprex (GNPX) posted quarterly Cash from Financing Activities of $13.4 million for Q1 2026, up 121.58% year-over-year from $6.0 million in Q1 2025, and up 23.38% quarter-over-quarter from $10.8 million in Q4 2025.
Genprex (GNPX) Cash from Financing Activities (2016 - 2026) Analysis & Trends
Genprex's Cash from Financing Activities history runs 10 years deep, the most recent figure standing at $13.4 million for Q1 2026.
- In Q1 2026, Cash from Financing Activities rose 121.58% year-over-year to $13.4 million; the TTM figure through Mar 2026 stood at $28.9 million (up 156.69% YoY), while the FY2025 annual figure was $21.5 million, up 79.32% from the prior year.
- Cash from Financing Activities for Q1 2026 stood at $13.4 million, up from $10.8 million in the prior quarter.
- The five-year high for Cash from Financing Activities was $13.4 million in Q1 2026, with the low at $4.0 in Q4 2023.
- The 5-year median for Cash from Financing Activities is $3.5 million (2024), against an average of $4.1 million.
- The sharpest annual moves came in 2023 and 2024: Cash from Financing Activities slumped 99.91% in 2023, then soared 99570150.0% in 2024.
- Genprex's Cash from Financing Activities stood at $4672.0 in 2022, then plunged by 99.91% to $4.0 in 2023, then jumped by 99570150.0% to $4.0 million in 2024, then jumped by 171.81% to $10.8 million in 2025, then advanced by 23.38% to $13.4 million in 2026.
- Business Quant data shows GNPX's Cash from Financing Activities at $13.4 million in Q1 2026, $10.8 million in Q4 2025, and $2.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 14.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -6.05 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 36.24 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -16.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 27.18 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -273.15 Mn |
| 10 | Genprex | 1.88 Mn | -13.28 Mn | - | 2.24 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 13.36 Mn |
| Mar 31, 2026 | 13.36 Mn |
| Dec 31, 2025 | 10.83 Mn |
| Dec 31, 2025 | 10.83 Mn |
| Sep 30, 2025 | 2.94 Mn |
| Sep 30, 2025 | 2.94 Mn |
| Jun 30, 2025 | 1.74 Mn |
| Jun 30, 2025 | 1.74 Mn |
| Mar 31, 2025 | 6.03 Mn |
| Mar 31, 2025 | 6.03 Mn |
| Dec 31, 2024 | 3.98 Mn |
| Dec 31, 2024 | 3.98 Mn |
| Sep 30, 2024 | 1.22 Mn |
| Sep 30, 2024 | 1.22 Mn |
| Jun 30, 2024 | 20,762.00 |
| Jun 30, 2024 | 20,762.00 |
| Mar 31, 2024 | 6.79 Mn |
| Mar 31, 2024 | 6.79 Mn |
| Dec 31, 2023 | 4.00 |
| Dec 31, 2023 | 4.00 |